"PharmaPoint: Hemophilia A and B" Published

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Several pharmaceutical companies, including Biogen Idec, Novo Nordisk, Bayer, Baxter and CSL Behring, will be launching long-acting rFVIII and rFIX therapies that aim to address this unmet need by providing increased protein half-life that potentially extends the time between prophylactic doses. The emergence of these new products, beginning in 2014 in the US and 2015 in the 5EU, will have a drastic effect on the hemophilia A and B treatment landscapes in the 7MM as patients adopt these premium-priced products. This sea change will be lead by Biogen Idec's Alprolix and Eloctate, which launched in the US in March and June 2014. Furthermore, Biogen's competitive pricing strategy for their new agents will encourage patient-switching and influence pricing that their competitors will be able to adopt. In the developing markets of Argentina and China, economic barriers prevent widespread adoption of recombinant prophylactic regimens, and pharmaceutical companies will face additional challenges in penetrating these markets during the forecast period.

Full Report Details at
- http://www.fastmr.com/prod/908923_pharmapoint_hemophilia_a_and_b_global_drug.aspx?afid=301

Highlights

Key Questions Answered

* How will the launch of long-acting rFVIII and rFIX replacement products affect the hemophilia A and B recombinant treatment landscape? How will Biogen Idec's pricing strategy impact market growth?
* How will launch timing of the long-acting products affect patient adoption over the forecast period?
* The unmet needs of hemophilia A and B patients in the US and 5EU are relatively low. What unmet needs will remain after the launch of the long-acting factors?
* How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU?
* The level of unmet needs for hemophilia patients in the developing markets of Argentina and China are higher compared to the established markets. Will the launch of long-acting products affect these markets? What additional opportunity will remain during the forecast period?

Key Findings

* Long-acting recombinant FVIII and FIX replacement therapies will displace the established short-acting products in the 7MM over the forecast period.
* Biogen Idec's competitive pricing strategy for their first-to-market long-acting rFVIII and rFIX products will impact overall pricing and market growth during the forecast period.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
- PharmaPoint: Hemophilia A and B - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
- PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Hemophilia A and B - Germany Drug Forecast and Market Analysis to 2022